Empirical antimicrobial guidelines are constantly evolving in response to laboratory susceptibility data. Broad spectrum agents exert a selection pressure gradually increasing antimicrobial resistance over time. In the level 3 neonatal intensive care unit (NICU), the majority of blood culture isolates are coagulase negative staphylococci (CoNS), which require appropriate empirical therapy.
Introduction
Survival rates amongst patients admitted to neonatal intensive care units (NICU) has increased significantly over the last ten years. One of the commonest interventions in patients admitted to NICUs is the initiation of antibiotics for the management of sepsis. Whilst there has been little change in the epidemiology of organisms associated with early onset sepsis (less than 72 hours), there has been increasing interest in the incidence and clinical relevance of coagulase negative staphylococci (CoNS). These organisms have the potential for pathogenicity in the neonates, the reasons for this include prematurity of the immune system, predisposing antibiotic consumption as well as the placement of intravascular catheters. The management of sepsis in NICUs is complex. There is a paucity of evidence based guidelines for the prescription of antimicrobials in children compared to the adult population, which results in a wide variation of guidelines between NICUs, often based on local experience and anecdotal evidence. Increasing levels of resistance in Gram negative organisms globally, as well as noticeable increases in the minimum inhibitory concentrations (MICs) of Gram positive organisms have specific implications in neonates. We aimed to look at isolates recovered from blood cultures, taken as part of routine clinical care to identify trends in resistance and map this to antimicrobial consumption in the unit over the last 5 years.
Methods
The NICU contains 6 intensive care cots and 6 high dependency cots alongside 22 special care cots. On average 7000 deliveries are managed by the unit each year, of a total of 11,500 deliveries across the Trust. Susceptibilities for Enterobacteraciae were unchanged over the study period, although a reduction in ampicillin resistance was noted. The susceptibilities that were analysed for CoNS were cloxacillin (CLX), ciprofloxacin (CIP), erythromycin (ERY), fusidic acid (FUS) and trimethoprim (TM). Best fit analyses were also plotted on the same graph (Fig 1) . Vancomycin MICs were not performed routinely in the laboratory. Consumption data was generated from dispensary records in the pharmacy. Numbers of vials on each antibiotic was plotted (Fig 2) . There are no WHO definitions for the defined daily dose (DDD)of antibiotics in neonates, and thus the numbers of vials was used as a rough guide of consumption data The 2011 consumption data in figure 2 only includes the first eight months of that calendar year. 
Discussion
Antimicrobial stewardship is an evidence based strategy to manage the emergence of increasingly resistant organisms through prudent prescribing. The focus on delivery of such programmes has increased over the last few years as noted by Bal et al (2011) , with particular emphasis on the role of broad spectrum antibiotics and deescalation. At the heart of the delivery of these new methodologies is a seamless interface between the laboratory susceptibility data, the medical microbiologist and the clinician. statistically significant (p>0.05) and could be attributable to statistical variability, the suggestion is that β-lactams are no longer appropriate in the empirical antimicrobial management of neonates in whom a CoNS is suspected to be significant. An increase in this resistance is in part due to the increasing use of β-lactams as first and second line agents in neonatal sepsis. This would suggest a more prominent role for glycopeptides as empiric agents when clinical sepsis is suspected. The use of techniques for the standardisation of blood sampling aim to reduce contamination rates, although early cessation of therapy is recommended if the blood culture result is deemed a contaminant. Marques-Minana et al (2010) noted that the use of glycopeptides in neonates is complicated by unpredictable pharmacokinetics, a narrow therapeutic window, and confusion about appropriate dosing regimens. Often therapeutic ranges of 10-20 mg/L for vancomycin are quoted (as in our unit), but these are difficult to achieve, resulting in sub-optimal therapy. For those children with bacteraemias due to meticillinresistant S. aureus (MRSA), Hussain et al (2011) demonstrated that lipopeptides have been successfully used guided by therapeutic drug monitoring. Stuart et al (2011) Liem et al (2010) have made attempts to draw up DDDs. These have not been standardised due to the wide variation of weights in the neonatal population. It is essential for units to monitor their antimicrobial resistance rates and consumption to inform future empirical and management guidelines.
